<< Back to News

FDA Approves TECENTRIQ® (atezolizumab) for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer

TECENTRIQ in combination with paclitaxel protein-bound* is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (PD-L1–stained tumor-infiltrating immune cells [IC] of any intensity covering ≥1% of the tumor area), as determined by an FDA-approved test.

This indication is approved under accelerated approval based on progression-free survival. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). *Paclitaxel protein-bound is also referred to as nab-paclitaxel (nab-pac).

Also Genentech is excited to share the news of a new 840 mg vial and new FDA-approved indication for a Genentech therapy. TECENTRIQ® (atezolizumab) is now available in a new 840 mg single-dose vial and has a new dosing schedule.

Please see the attached TECENTRIQ 840 mg Now Available Flashcard, as well as the TECENTRIQ full Prescribing Information, for additional Important Safety Information.

Full Prescribing Information:

https://www.gene.com/download/pdf/tecentriq_prescribing.pdf

TECENTRIQ Flashcard